News and Trends 28 Jun 2022
Biogen, citing insurance challenges, shutters one of its Aduhelm studies
A company says it was forced to end an observational trial of Alzheimer’s drug, Aduhelm, after a ruling by US federal insurance program, Medicare. Biogen said a recent coverage decision by Medicare has forced it to abandon the trial of the drug after enrolling just 29 participants. The company said it made the decision to […]